QUANTIB® Prostate
Quantib
Product specifications |
Information source:
Vendor
Last updated: Feb. 23, 2023 |
General | |
---|---|
Product name | QUANTIB® Prostate |
Company | Quantib |
Subspeciality | Abdomen |
Modality | MR |
Disease targeted | Prostate cancer |
Key-features | Prostate gland and zone volume measurements, PSA density calculation, AI-supported ROI segmentation, PI-RADS v.2.1 scoring support, structured report |
Suggested use | During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion |
Data characteristics | |
Population | Prostate MRI scans with suspicion of prostate cancer |
Input | MRI, T2, DWI, DCE (optional) |
Input format | DICOM |
Output | Segmentation overlays, segmentation series, a structured report with key images and PI-RADS |
Output format | DICOM |
Technology | |
Integration | Integration in standard reading environment (PACS), DICOM-based integration via own zero footprint AI platform |
Deployment | Locally on dedicated hardware, Cloud-based |
Trigger for analysis | Automatically, right after the image acquisition, On demand, triggered by a user through e.g. a button click, image upload, etc. |
Processing time | 1 - 10 minutes |
Certification | |
CE
|
Certified,
Class IIb
, MDR
|
FDA
|
510(k) cleared, Class II |
Market presence | |
On market since | 10-2020 |
Distribution channels | Bayer Calantic Digital Solutions |
Countries present (clinical, non-research use) | |
Paying clinical customers (institutes) | |
Research/test users (institutes) | |
Pricing | |
Pricing model | Pay-per-use, Subscription |
Based on | Number of installations, Number of analyses |
Evidence | |
Peer reviewed papers on performance |
|
Non-peer reviewed papers on performance | |
Other relevant papers |